Page 70 - MEMORIA ANUAL 2019 SEHH-FEHH

Programa EsPañol dE TraTamiEnTos En HEmaTología (PETHEma)
MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragán E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Laza- revic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Rácil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019 Oct 10;37(29):2632-42. doi: 10.1200/JCO.19.00416.
• Rosiñol L, Oriol A, Ríos R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Mar- tínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, Gon- zález-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Ca- sado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019 Oct 17;134(16):1337-45. doi: 10.1182/blood.2019000241.
• Rambaldi A, Ribera JM, Kantarjian HM, Dombret H, Ottmann OG, Stein AS, Tuglus CA, Zhao X, Kim C, Martinelli G. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chro- mosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 2020 Jan 15;126(2):304-10. doi: 10.1002/cncr.32558.
• Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, Sanz MÁ. Up- date on management and progress of novel therapeutics for R/R AML: an Iberi- an expert panel consensus. Ann Hematol. 2019 Nov;98(11):2467-83. doi: 10.1007/ s00277-019-03820-w.
• Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J. The effects of different schedules of bort- ezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leuk Lymphoma. 2020 Mar;61(3):680-90. doi: 10.1080/10428194.2019.1675881.
• Sobas M, Rodríguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J, García-Álvarez F, Gil C, Brunet S, Bergua J, González-Campos J, Ribera JM, Tormo M, González M, Fer- nández I, Benavente C, González-Sanmiguel JD, Esteve J, Pérez-Encinas M, Salamero O, Manso F, Lowenberg B, Sanz MA, Montesinos P; PETHEMA, HOVON, PALG, GATLA
70